Roche reveals the availability of the inaugural commercial supply of Vabismo (faricimab), a groundbreaking treatment for neovascular (“wet”) age-related macular degeneration and visual impairment caused by diabetic macular edema. Shipments of the drug can be carried out from the warehouse of Rosh-Moscow JSC from July 27, 2023 under existing supply contracts.
Faricimab is a monoclonal antibody used for the treatment of neovascular age-related macular degeneration and diabetic macular edema. Faricimab is the first bispecific monoclonal antibody to target both vascular endothelial growth factor and angiopoietin 2. By targeting these pathways, faricimab stabilizes blood vessels in the retina. It is given by intravitreal injection (injection into the eye) by an ophthalmologist. Faricimab was approved for medical use in the United States in January 2022, and in the European Union in September 2022.
